CIPRALEX -20MG 20 MG
ESCITALOPRAM (ESCITALOPRAM OXALATE) : 20 MG · DIN 02263254 · LUNDBECK CANADA INC
Health Canada status: MARKETED
What is CIPRALEX -20MG?
CIPRALEX -20MG 20 MG contains ESCITALOPRAM (ESCITALOPRAM OXALATE) : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02263254, held by LUNDBECK CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 14-Feb-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CIPRALEX -20MG used for?
CIPRALEX (escitalopram oxalate) is indicated in adults for: the symptomatic relief of Major Depressive Disorder (MDD). The efficacy of CIPRALEX in maintaining an antidepressant response, in patients with major depressive disorder who responded during an 8-week, acute-treatment phase while taking CIPRALEX and were then observed for relapse during a period of up to 36 weeks, was demonstrated in a placebo-controlled trial. the symptomatic relief of anxiety causing clinically significant distress in patients with Generalized Anxiety Disorder (GAD). The efficacy of CIPRALEX in maintaining anxiolytic response for at least 6 months in patients with GAD was demonstrated in a long-term placebo-controlled trial (in patients who had initially responded to CIPRALEX during a 12-week open-label phase. the symptomatic relief of obsessive-compulsive disorder (OCD). The obsessions and compulsions must be experienced as intrusive, markedly distressing, time consuming or interfering significantly with the person’s social or occupational functioning. The efficacy of CIPRALEX in maintaining an anti-obsessive response for up to 6 months in patients with OCD was demonstrated in a long-term placebo-controlled trial in patients who initially responded to 16 weeks of CIPRALEX open-label treatment.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02263254 |
|---|---|
| Brand name | CIPRALEX -20MG |
| Generic / active ingredient | ESCITALOPRAM (ESCITALOPRAM OXALATE) : 20 MG |
| Manufacturer | LUNDBECK CANADA INC |
| Strength | 20 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AB10 ESCITALOPRAM |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 14-Feb-2005 |
| Original market date | 2005-02-15 00:00:00 |
How is it stored and handled?
null
How is it supplied?
5 mg: Blister packages of 30 and in bottles of 100. 10 mg: Blister packages of 7 and 30 and bottles of 100 and 200. 15 mg: Blister packages of 30 and in bottles of 100. 20 mg: Blister packages of 30 and in bottles of 100.
Is ESCITALOPRAM in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N06AB10 ESCITALOPRAM. 47 of 101 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-ESCITALOPRAM | 10 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02434652 |
| ACH-ESCITALOPRAM | 20 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02434660 |
| ACT ESCITALOPRAM ODT | 10 MG | TABLET (ORALLY DISINTEGRATING) | TEVA CANADA LIMITED | MARKETED | DIN 02454297 |
| ACT ESCITALOPRAM ODT | 20 MG | TABLET (ORALLY DISINTEGRATING) | TEVA CANADA LIMITED | MARKETED | DIN 02454300 |
| AG-ESCITALOPRAM | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02477742 |
| AG-ESCITALOPRAM | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02477769 |
| AG-ESCITALOPRAM TABLETS | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02510944 |
| AG-ESCITALOPRAM TABLETS | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02510952 |
| APO-ESCITALOPRAM | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02295016 |
| APO-ESCITALOPRAM | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02295024 |
Who else supplies ESCITALOPRAM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ESCITALOPRAM appears in 1361 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.